Quick Answer
Acrivon Therapeutics, Inc. reported Research And Development Expense of $59.99 million for the year ending 2025.
- Acrivon Therapeutics, Inc. showed a decrease of -6.3% in Research And Development Expense from 2024 to 2025.
- This data is from Acrivon Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 4 years of available data (2022 to 2025), Acrivon Therapeutics, Inc.'s Research And Development Expense has grown by 150.5%.
- Historical annual values: Fiscal year 2025: $59.99 million | Fiscal year 2024: $63.99 million | Fiscal year 2023: $46.02 million | Fiscal year 2022: $23.95 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: